Physician profile
Arthur E Richert
NPI 1013127935
$6,694.52
in general payments reported to CMS, 2019-2025
32 companies · $847 in 2025
The $847 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $533 · 2021: $1,351 · 2022: $1,327 · 2023: $981 · 2024: $910 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,639 · Education: $99.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,638.68 |
| Education | $99.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,579.28 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Abbvie INC. | $1,443.43 | 2019-2025 | |
| Janssen Biotech, INC. | $972.46 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $430.11 | 2021-2024 | Zeposia |
| Olympus America INC. | $366.59 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $361.07 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $188.72 | 2021-2024 | |
| Evoke Pharma, INC. | $158.13 | 2022 | |
| Nestle Healthcare Nutrition INC. | $149.62 | 2020-2022 | |
| Ardelyx, INC. | $127.52 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $96.57 | 2025 | Sucraid |
| Braintree Laboratories, INC. | $73.75 | 2019-2020 | |
| Boston Scientific Corporation | $70.50 | 2022-2025 | General - Hemostasis, Compliance Endokit, Captivator II |
| Ipsen Biopharmaceuticals, INC | $69.98 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $65.66 | 2023-2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $64.87 | 2020-2025 | |
| Mauna Kea Technologies, INC. | $56.31 | 2024-2025 | |
| Shire North American Group INC | $49.65 | 2019 | |
| Medtronic, INC. | $45.05 | 2022 | |
| Merck Sharp & Dohme LLC | $41.89 | 2022-2023 | Dificid |
| Daiichi Sankyo INC. | $40.74 | 2019-2024 | Enhertu |
| Redhill Biopharma INC. | $39.68 | 2020-2023 | |
| Novo Nordisk INC | $37.21 | 2025 | Wegovy |
| Gilead Sciences, INC. | $28.54 | 2022-2023 | |
| Amgen INC. | $25.92 | 2021 | |
| Ferring Pharmaceuticals INC. | $23.12 | 2019 | |
| Stryker Corporation | $19.41 | 2023 | Neptune |
| Celltrion USA INC. | $15.39 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $14.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.46 | 2023 | Cyltezo |
| Cook Medical LLC | $13.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Richert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.